key: cord-0898091-9a5yrtsl
authors: Cunningham, Louise; Kimber, Ian; Basketter, David; Simmonds, Peter; McSweeney, Sheila; Tziotzios, Christos; McFadden, John P.
title: Perforin, COVID‐19 and a possible pathogenic auto‐inflammatory feedback loop
date: 2021-09-22
journal: Scand J Immunol
DOI: 10.1111/sji.13102
sha: ea37986eb334e2892eb63b84e0e50fdb17d34b2a
doc_id: 898091
cord_uid: 9a5yrtsl

During COVID‐19 infection, reduced function of natural killer (NK) cells can lead to both compromised viral clearance and dysregulation of the immune response. Such dysregulation leads to overproduction of cytokines, a raised neutrophil/lymphocyte ratio and monocytosis. This in turn increases IL‐6 expression, which promotes scar and thrombus formation. Excess IL‐6 also leads to a further reduction in NK function through downregulation of perforin expression, therefore forming a pathogenic auto‐inflammatory feedback loop. The perforin/granzyme system of cytotoxicity is the main mechanism through which NK cells and cytotoxic T lymphocytes eliminate virally infected host cells, as well as being central to their role in regulating immune responses to microbial infection. Here, we present epidemiological evidence suggesting an association between perforin expression and resistance to COVID‐19. In addition, we outline the manner in which a pathogenic auto‐inflammatory feedback loop could operate and the relationship of this loop to genes associated with severe COVID‐19. Such an auto‐inflammatory loop may be amenable to synergistic multimodal therapy.

Coronavirus disease 2019 (COVID-19) caused by the virus named SARS-coronavirus-2 (SARS-CoV-2) originated in Wuhan in 2019 and rapidly became a global pandemic. It is a highly infectious viral disease with variable morbidity and mortality. Clinical presentations and complications range from asymptomatic infections to death. Host susceptibility appears to play a key role in determining clinical outcomes, but heterogeneity in susceptibility remains to be fully explained.

Type I and II interferons (IFNs), Fas ligand (Fas-L) and perforin/granzyme apoptotic pathways are three of the most important components of immune defence mechanisms against viral pathogens. Type I IFNs (α and β) are produced early in viral infection and are known to stimulate antiviral genes as well as being regulators of the innate response, including natural killer (NK) cells. 1 Type II IFN (IFN-γ) also forms a part of the innate antiviral response. It is produced by NK cells and activated T lymphocytes, other producers to include innate lymphoid cells type 1 and macrophages, and it promotes Th1 adaptive immune responses. 1 Fas receptor-Fas ligand signalling is involved in apoptosis of virus-infected target cells and contributes to the cytotoxic activity of both NK and cytotoxic T cells (CTL). 2 Perforin/granzyme-induced apoptosis, as discussed below, is the major pathway through which cytotoxic lymphocytes eliminate virally infected host cells. 3 Factors associated with alterations in NK and cytotoxic immune cell function, such as increased or decreased granzyme system of cytotoxicity is the main mechanism through which NK cells and cytotoxic T lymphocytes eliminate virally infected host cells, as well as being central to their role in regulating immune responses to microbial infection. Here, we present epidemiological evidence suggesting an association between perforin expression and resistance to COVID-19. In addition, we outline the manner in which a pathogenic auto-inflammatory feedback loop could operate and the relationship of this loop to genes associated with severe COVID-19. Such an autoinflammatory loop may be amenable to synergistic multimodal therapy. perforin expression, are likely to impact on resistance or susceptibility to severe COVID-19 infection. Here, we examine the evidence for an association between the expression and function of perforin and susceptibility to severe COVID-19 infection. We also review how reduced cytotoxic lymphocyte function (with a particular focus on NK cell activity), associated with compromised perforin expression, might result not only in decreased virus clearance, but also dysregulation of the immune response, thereby creating a pathogenic auto-inflammatory feedback loop.

Perforin is expressed by both innate and adaptive NK cells, NKT cells, cytotoxic CD8+ T cells (CTL), Treg cells and γδ T cells. 4 NK cells and CTL, as cytotoxic lymphocytes, play key roles in the destruction of virally infected host cells. This is achieved via toxic proteases called granzymes (granzyme B having the most potent pro-apoptotic function) and the antimicrobial peptide granulysin. 4 Following creation of an immune synapse between cytotoxic lymphocytes and virally infected cells, perforin generates pores in the target cell membrane allowing entry of effector molecules and subsequent cell death. 4 NK cells can engage with and kill target cells via the perforin pathway within hours of encountering foreign antigen (due to constitutively expressed perforin mRNA), whereas naive CTLs express the highest level of perforin mRNA and protein approximately one week after T cell receptor stimulation. 5 Perforin also plays a regulatory role in T cell activation as well as in destroying cancer cells. 4 It must be appreciated, however, that perforin is also expressed by other immune cells and that NK cell function generates antiviral effects through several mechanisms other than perforin/granzyme action. 6 1.2 | Epidemiological factors associating perforin expression and resistance to severe COVID-19 symptoms and mortality

Old age, particularly over 70 years, is a significant risk factor for mortality from SARS-CoV-2 infection. 7 Expression of perforin and NK cell cytotoxic function declines significantly after the age of 70 years. 8 Reduced release and binding of perforin with target cells at the immunological synapse appear to be a major cause of the age-related decline in NK cell cytotoxicity. 9 Perforin expression has been found to be significantly higher in children compared with both male and female adults. 8 Clinical manifestations of COVID-19 disease are much less common in children compared with adults, and hospitalizations for severe disease and deaths are rare. 10 Females have significantly higher levels of perforin expression compared with age-matched males. 8 Male gender is a prominent risk factor for COVID-19 mortality, whereas female sex is protective and gender mortality ratio M:F can be as high as 3:1. 7 FasL and IFN-γ expression follow similar patterns with some notable exceptions however, such as lower IFN-γ production in childhood. 11 There are, of course, many biological differences between males and females, and between the young and the elderly, that might also contribute to varying resistance to COVID-19, but it is intriguing that associations with disease severity mirror perforin levels in these groups.

Obesity, a prominent adverse risk factor for COVID-19, is associated with reduced perforin expression and NK cells from obese individuals have reduced cytolytic activity compared with those from lean individuals. 12 Aetiological factors for this include lipid accumulation in NK cells which reduces perforin, granzyme B and IFN-γ secretion and the negative inhibition of NK activity by adipokines (cytokines secreted by adipose tissue) including interleukin(IL)-6. 13, 14 Conversely, and interestingly, perforin deficiency, related to its function in immune regulation, may predispose to obesity, glucose intolerance and insulin resistance as identified in studies with perforindeficient mice. 15 Meta-analyses have revealed that obese individuals are at greater risk of: (i) testing positive for SARS-CoV-2, (ii) hospitalization, (iii) ICU admission and (iv) mortality from COVID-19 disease (by 48% increase in deaths). 16 

The associations of perforin with heart disease are complex. However, reduced NK activity in coronary heart disease has been confirmed by several reports. [17] [18] [19] [20] Cardiovascular disease has also been reported as having one of the highest co-morbid associations with COVID-19. 21 In both established Type 1 and Type 2 diabetes, lower levels of perforin expression are reported. 22, 23 Diabetes, of either type, has also been reported as being among the commoner comorbidities with severe COVID-19 disease. 21 

The relatively well-tolerated drug metformin has been shown to increase perforin and granzyme B expression at dose levels used in the treatment of diabetes. 24 Kow et al undertook a meta-analysis of the use of metformin and COVID-19 outcomes. 25 This revealed that there was a reduction in mortality among diabetic patients who were receiving metformin medication compared with diabetic patients who were not. Oestrogens have been shown to significantly increase perforin expression, 26 whilst antioestrogens reduce perforin expression. 27 Costeira et al, using a self-reporting 'mobile app' system, studied over 500 000 women for associations between COVID-19 infection and their oestrogen status. 28 Their findings support a protective effect of oestrogen on COVID-19 infection and severity.

In summary, several epidemiological factors appear to associate perforin expression and NK cell function with resistance to COVID-19.

The literature regarding NK cell function and phenotype in patients with COVID-19 and COVID ARDS is not uniform. This perhaps is not surprising as the studies reported cover different definitions of 'severe', differing ethnicity and other patient demographics and the examination of different compartments of NK cells as well as time points in disease course. However, certain trends are observed consistent with perforin performing an important role in antiviral activity and reduced/dysregulated NK function in severe COVID-19. Li et al found reduced perforin and granzyme B expression by peripheral blood NK cells in hospitalised patients. 29 D'Allesandro et al reported reduced numbers of blood NK cells in patients with severe COVID compared with those with non-severe illness. 30 Maucourant et al found that absolute numbers of blood NK cells (both cytokine-producing CD56 bright and cytotoxic CD56 dim cells) were significantly reduced in COVID-19-infected patients, and this was more apparent in severe cases (ICU/high dependency unit, non-invasive/ mechanical ventilation). The reduced number of remaining CD56 bright and CD56 dim NK cells did show 'arming' with significant perforin expression in COVID patients. 31 Patients with severe disease also had distinct adaptive NK immunotypes with NKG2C, perforin and ksp37 (killerspecific secretory protein that is usually co-expressed with perforin 32 ) expression. 31 NKG2C interacts with its ligand HLA-E to mediate NK cytotoxic and cytokine response to virally infected cells. 33 Gene variants with deletion of NKG2C receptor are a highly significant risk factor for severe COVID-19. 33 Li et al demonstrated lower NK cells with 'exhaustion' of NK cells as demonstrated by programmed death, PD-1, expression in patients with advanced COVID-19 and severe symptoms. 29 Reduced NK cytotoxicity in severe COVID-19 was related to increased IL-6 levels and treatment with anti-IL6 biologic therapy restored cytotoxic potential of NK cells. 34 

The perforin amino acid substitution Ala91Val (A91V) impairs perforin activity in several ways: it reduces protein stability and slows intracellular trafficking, which can reduce cytotoxicity by 50%-90%. 4 Twenty-two previously healthy patients aged 24-52 who had been admitted to intensive care with COVID-19 infection were tested for the common perforin gene polymorphism A91V. Two of the patients harboured this variant and both died, whereas only one of the A91V-negative patients died. 35 Although it is tempting to interpret the association of this mutation with defective perforin function as contributing to the death from COVID-19, this early report comprising a very small number of cases awaits further corroboration Perforin has a significant role in regulating T cell activation and activity, including regulating cytokine release. 5 Defective perforin function, as seen in patients with perforin gene mutations in familial haemophagocytic lymphohistiocytosis (fHLH), can be associated with 'cytokine storm'. Failed killing of the target cell leads to prolonged attachment, resulting in many successive rounds of Ca 2+ flux into the cytotoxic cell, which triggers substantial secretion of pro-inflammatory cytokines and chemokines. 4 In turn, secreted IFN-γ causes hyperactivation of the myeloid cellular compartment and stimulates macrophages to secrete IL-6. This cytokine is considered the main instigator of fatal systemic inflammation in fHLH. 4 'Cytokine storms' (also known as macrophage activation syndrome [MAS] or secondary HLH [sHLH]) are also one of the major factors leading to COVID-19-associated mortality. [36] [37] [38] Laboratory and clinical features of sHLH resemble fHLH (associated with homozygous mutations in the perforin cytolytic pathway). sHLH is a much more common entity and now recognized as being associated with heterozygous mutations (possibly functioning as hypomorphic or partial dominant-negative alleles) in the same perforin pathway genes that can predispose to similar cytokine storm-like manifestations including from specific viral triggers. 39 Indeed, examples of other causative genes include SH2P1A involved in viral control. 39 Of note, mutations in perforin and related genes have previously been associated with sHLH/MAS-like presentations in patients who died from H1N1 influenza. 40 Recently, germline variants in UNC13D and AP3B1, both HLH-related genes, were found to be associated with COVID-19 plus high cytokine levels and mortality. 41 Black and Asian ethnicity represents another substantial risk factor for severe COVID-19, and although racial inequalities are acknowledged as an important factor in this risk disparity (including inequitable access to health, overcrowded living conditions, engagement in essential work), 42 genetic susceptibility may also be relevant. Single nucleotide polymorphisms (SNPs) in the perforin gene, particularly those associated with decreased activity of the protein, have been linked with reduced population distance from the equator due to equator-associated selection pressure from infectious diseases. 43 It is proposed that in some diseases, such as falciparum-associated cerebral malaria, these SNPs can confer a host survival advantage (relating to a protective effect of perforin deficiency on pathogen-associated blood-brain barrier disruption). 43 We postulate that individuals of African or Asian ancestry possessing such SNPs (such as the higher prevalence of Arg232His in South Asian populations) have an elevated susceptibility to COVID-19 and/or cytokine storms via impairment of perforin function.

Four important steps are involved in the potential production of a pathogenic auto-inflammatory feedback loop ( Figure 1 ).

Perforin-deficient mice have been shown to induce lymphocyte hyperactivation with increased production of cytokines in response to viral infection. 5 As outlined above, defective perforin function, as seen in patients with fHLH, is also associated with 'cytokine storm' resulting from dysregulation of the immune response to infection. In COVID-19 cytokine storm, NK cytolytic capacity and perforin protein levels may be consumed by effecting antiviral activity and individuals with lower baseline expression may be more prone to 'exhaustion', which could lead to defective regulation of the immune response.

Five studies assessing the cytokine release in COVID-19  reported increase of IL-1α, IL-1β, IL-1Ra, IL-6, IL-8, IL-10,  IL-17, IL-18 , tumour necrosis factor-α (TNF-α), IFN-α 2, IFN-γ, granulocyte colony-stimulating factor (G-CSF). 44 Some are produced by neutrophils and IL-8, IL-17 and TNF-α promote or are chemotactic for neutrophils. [45] [46] [47] High-serum IL-6, IL-8 and TNF-α levels at the time of hospitalization were strong and independent predictors of patient mortality. 48 Severe COVID-19 is also associated with an increased neutrophil/lymphocyte ratio (NLR), suggestive of systemic inflammation and itself indicative of a poor prognosis. 49 Increased monocyte levels are also present, and these leucocytes are potent producers of IL-6 in severe COVID-19. 50 Neutrophils can promote the expression of IL-6 51 and also express cytokines such as TNF-α and IL-17 that can then, in turn, also promote IL-6 expression. 52 

IL-6 is a multifunctional cytokine synthesized by immune and stromal cells in response to danger signals 36 and an initiator of innate defence. 53 Raised IL-6 levels, as stated, are associated with COVID-19-related mortality, 36 and the daily change in the ratio of IL-6 to IL-10 (an anti-inflammatory cytokine) in patients hospitalized with COVID-19 forms the basis of a new prediction tool for disease severity (raised IL-6/IL-10 ratios being associated with a poorer prognosis). 54 Elevated levels of IL-6 have also been observed in conditions associated with a higher risk of severe COVID-19 including obesity, chronic heart disease and diabetes. 55, 56 Raised IL-6 is associated with scarring, 57 thrombosis 58 and neutrophilia 59 -all features of severe COVID-19-related lung disease in particular.

IL-6 is known to reduce both perforin and granzyme expression. 60 Raised IL-6 cytokine levels have the potential to impact negatively on both NK cells and CTL antiviral activity, which can lead to a reduction in both viral clearance and immunoregulation. 34 Therefore, a detrimental pathogenic feedback loop could evolve.

All four steps described above have been documented as having a poor prognosis. 34, 61 It is possible also that this type of pathogenic feedback loop could also be operative in other diverse, neutrophilic autoinflammatory diseases such as rheumatoid arthritis or hidradenitis suppurativa.

The results of the GenOMICC (Genetics of Mortality In Critical Care) genome-wide association study (GWAS) in 2244 critically ill COVID-19 patients from 208 UK intensive care units were recently reported. 62 The study identified and replicated novel genome-wide significant associations at four gene cluster sites associated with genes encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), tyrosine kinase 2 (TYK2), dipeptidyl peptidase 9 (DPP9) and (the IFN-α receptor gene) IFNAR2. Using Mendelian randomization, the authors found evidence of a causal link for low expression of IFNAR2 and high expression of TYK2 with life-threatening disease. Furthermore, transcriptome-wide association in lung tissue revealed that high lung expression of the receptor CCR2 was associated with severe COVID-19. 62 A more recent integrative genetic analysis re-affirmed the central role of inflammatory response and antiviral host response signalling, including CXCR6, CCR9, CCR5, XCR1, IFNAR2, IL10RB, OAS1, OAS3 and JAK-STAT signalling pathways. 63 Whilst the implicated encoded proteins regulate a multitude of immunological pathways potentially underpinning host response to viral pathogens, four have the potential to impact on the feedback loop outlined in Figure 1 . As regards IFNAR2 (which encodes for a ubiquitously expressed receptor which binds Type 1 IFNs), IFN-α has been reported to increase both perforin and perforin mRNA expression. 64, 65 TYK2, which is a part of the Janus kinase family of enzymes, is involved in promoting perforin-deficient associated Pro-inflammatory cytokines cause neutrophil accumulation and activation, with an increased neutrophil/lymphocyte ratio. (4) Secretion of interleukin-6 is promoted, which contributes to scarring and thrombosis associated with severe COVID-19-related lung disease. Raised interleukin-6 secretion will also promote the suppression of perforin expression and decreased natural cell killer function, completing a pathogenic feedback loop. At each stage in the cycle, therapeutic strategies are described and relevant genes in which variants associated with severe SARS-CoV-2 infection have been identified are highlighted in yellow cytokine storm. 66 DPP9 can promote both IL-6 and TNF-α secretion. 67 CCR2 is expressed by different cells and can be involved in migration of cells such as monocytes/macrophages and neutrophils. It has been shown in the case of influenza that a significant proportion of NK cells migrate in a CCR2-dependent fashion. 68 Other genetic/epigenetic studies have highlighted the roles of IFN-mediated immune signalling, chemokine, chemotaxis and other impaired immune responses. 69 Meanwhile, interrogation of the STRING (Search Tool for the Retrieval of Interacting Genes/ Proteins) database confirms the central role of perforin in the protein network of the identified associations ( Figure 2 ).

In essence, these identified genetic mutations associated with severe COVID-19 disease impact expression and/or function of key players in our proposed autoinflammatory pathogenic feedback loop ( Figure 1 ).

The presence of a pathogenic feedback loop would suggest two pharmacological approaches. Firstly, combining drugs to 'attack' different parts of the loop, and secondly that earlier treatment may be more efficacious. Tocilizumab, an anti-IL6 receptor biologic, has already been given a UK license for COVID therapy. Dapsone, a drug with known anti-neutrophil and TNF-α properties, 70 has been advocated as a potential therapy 71 and is currently undergoing clinical trials to evaluate this further (DAP-CORONA). Janus kinase (JAK) inhibitors can ameliorate inflammatory models of cytokine storm amongst perforin deficient (−/−) mice. 66 IL-1 receptor antagonist anakinra has been effective in treating some cytokine storm syndromes. 72 Corticosteroid therapy has multiple potential points of action, including inhibiting neutrophilic function, 73 decreasing TNF-α and IL-6 levels 74 as F I G U R E 2 Protein network association analysis for perforin (PRF1) using the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database; network nodes represent proteins; edges represent protein-protein associations well as inhibiting scar formation. 75 Initial studies looking at combined and/or early drug therapy, such as the addition of anakinra or tocilizumab to systemic corticosteroids, have shown promise. 76, 77 

Since the onset of the COVID-19 pandemic, several factors have been identified which are associated either with disease resistance (including childhood, female gender, normal range body mass index, oestrogen medication) or with susceptibility (aged 70 years and over, male gender, obesity, cardiovascular disease, diabetes). All these factors also have in common an association with raised or decreased perforin expression/function, suggesting that perforin is an important mediator of resistance to COVID-19 infection. Integrating this information with pathways involving NK cell/perforin suggests the possibility of a pathogenic auto-inflammatory feedback loop ( Figure 1 ).

All authors contributed to the writing, editing and reviewing of this paper and approved the final version.

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

https://orcid. org/0000-0002-2009-3588

The dual nature of type I and type II Interferons

Fas/FasL pathway participates in regulation of antiviral and inflammatory response during mousepox infection of lungs

Heterozygosity for the common perforin mutation, p. A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals

Perforin and granzymes: function, dysfunction and human pathology

Perforin is a critical physiologic regulator of T-cell activation

Natural killer cells: development, maturation, and clinical utilization

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells

Reduced release and binding of perforin at the immunological synapse underlies the age-related decline in natural killer cell cytotoxicity

COVID-19 and multisystem inflammatory syndrome in children and adolescents

Influence of age and other factors on cytokine expression profiles in healthy children-a systematic review

Antibody responses to SARS-CoV-2 in patients with COVID-19

Metabolic reprogramming of natural killer cells in obesity limits antitumor responses

Obesity-associated alterations of natural killer cells and immunosurveillance of cancer

Perforin is a novel immune regulator of obesity-related insulin resistance

Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships

NK cell compartment in patients with coronary heart disease

Loss of natural killer cell activity in patients with coronary artery disease

Increased expression of T cell immunoglobulin-and mucin domain-containing molecule-3 on natural killer cells in atherogenesis

Natural killer (NK) cell deficit in coronary artery disease: no aberrations in phenotype but sustained reduction of NK cells is associated with low-grade inflammation

The Impact of pre-existing comorbidities and therapeutic interventions on COVID-19

Type 2 diabetes mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary tuberculosis

Peripheral blood cytotoxic lymphocyte gene transcript levels differ in patients with long-term type 1 diabetes compared to normal controls

Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer

Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis

Estradiol-dependent perforin expression by human regulatory T-cells

Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer

Estrogen and COVID-19 symptoms: associations in women from the COVID symptom study. medRxiv

Elevated exhaustion levels of NK and CD8(+) T cells as indicators for progression and prognosis of COVID-19 disease

Peripheral biomarkers' panel for severe COVID-19 patients

Natural killer cell immunotypes related to COVID-19 disease severity

A novel serum protein that is selectively produced by cytotoxic lymphocytes

Puchhammer-Stöckl E. Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Perforin gene variant A91V in young patients with severe COVID-19

The role of Interleukin 6 inhibitors in therapy of severe COVID-19

Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19

Longitudinal Immune Profiling Reveals Distinct Features Of COVID-19 Pathogenesis

The genetics of macrophage activation syndrome

Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 Influenza

Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms

Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis

Human perforin gene variation is geographically distributed

Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider

Frontline science: tumor necrosis factor-α stimulation and priming of human neutrophil granule exocytosis

IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma

TNFalpha and IL-8 are upregulated in the epidermis of normal human skin after UVB exposure: correlation with neutrophil accumulation and E-selectin expression

An inflammatory cytokine signature predicts COVID-19 severity and survival

The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients

Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients

Neutrophil-derived cytokines: facts beyond expression

Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members

Mitigating coronavirus induced dysfunctional immunity for at-risk populations in COVID-19: trained immunity, BCG and

A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells

Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure

IL-6 signaling pathway in keloids: a target for pharmacologic intervention?

IL (Interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p

IL-6 plays an essential role in neutrophilia under inflammation

Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome

Unique immunological profile in patients with COVID-19

Genetic mechanisms of critical illness in Covid-19

Integrative analyses identify susceptibility genes underlying COVID-19 hospitalization. medRxiv

Interferonalpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway

Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis

CCR2 defines a distinct population of NK cells and mediates their migration during influenza virus infection in mice

Immunogenetic association underlying severe COVID-19

Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections

Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

COVID-19: consider cytokine storm syndromes and immunosuppression

How glucocorticoids affect the neutrophil life

Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies

Are corticosteroids effective for prevention of scar formation after seconddegree skin burn?

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial